Chloe C. McAlister, Zu‐hua Gao, Vivian C. McAlister, Rekha Gupta, James R. Wright, Allan S. MacDonald, Kevork Peltekian – 30 January 2004 – The mechanism by which a liver transplantation might protect a simultaneous kidney transplant in a crossmatch‐positive recipient is unknown. Flow cytometry crossmatch (FCXM) has increased the sensitivity of donor‐specific antibody (DSA) detection compared with complement‐dependant cytotoxicity (CDC).

Pietro Vajro, Claudia Mandato, Adriana Franzese, Stefania Lucariello – 30 January 2004

Masashi Yoneda, Takenao Hasegawa, Kimihide Nakamura, Masasya Tamano, Toru Kono, Akira Terano – 30 January 2004

Debbie L. Shawcross, Nathan A. Davies, Rajeshwar P. Mookerjee, Peter C. Hayes, Roger Williams, Alistair Lee, Rajiv Jalan – 30 January 2004 – There is increasing evidence that terlipressin is useful in patients with cirrhosis and hepatorenal syndrome, but there are no data of its use in patients with acute liver failure (ALF) in whom hepatorenal syndrome is common. Although terlipressin produces systemic vasoconstriction, it produces cerebral vasodilatation and may increase cerebral blood flow (CBF). Increased CBF contributes to intracranial hypertension in patients with ALF.

Evelyn Zeindl‐Eberhart, Sibylle Haraida, Sibylle Liebmann, Peter Roman Jungblut, Stephanie Lamer, Doris Mayer, Gundula Jäger, Stephen Chung, Hartmut Manfred Rabes – 30 January 2004 – The proteomic approach is a valuable tool to detect and identify proteins that are associated with cancer. In previous investigations on experimentally induced rat hepatomas, we detected aldose reductase‐like protein (ARLP) as a highly significant marker protein. Our present study was intended to look for the presence of similar tumor‐associated marker proteins on human hepatocellular carcinomas (HCC).

Neil Kaplowitz – 30 January 2004

Jordi Bruix, Josep M. Llovet – 30 January 2004

Timothy M. Pawlik, Nestor F. Esnaola, Jean‐Nicolas Vauthey – 30 January 2004 – Recently, the International Cooperative Study Group for hepatocellular carcinoma (HCC) proposed a new staging based on data from multiple centers across the world. The new TNM staging has been shown to be more accurate in the prognostic classification of patients after resection for HCC. This staging is the basis for the new TNM for HCC approved by the AJCC (American Joint Committee on Cancer) and UICC (Union Internationale Contre le Cancer).

Tito Livraghi, Franca Meloni, Alberto Morabito, Claudio Vettori – 30 January 2004 – The best treatment policy for some patients with hepatocellular carcinoma (HCC) and compensated cirrhosis is still controversial. The aim of this study was to evaluate the long‐term survival and related prognostic factors of patients with early and intermediate HCC (Liver Unit of Barcelona classification) treated in a radiologic referral center by a multimodal image‐guided tailored therapy (MIGTT), applied over time, choosing the procedure patient by patient according to the presentation of the disease.

John G. O'Grady – 30 January 2004